A panel of thoracic oncologists have a comprehensive discussion on the treatment of HER2 non–small cell lung cancer, covering diagnosis, therapies, clinical trials, and unmet needs in the treatment space.
EP. 4: DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC
April 24th 2024Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
EP. 6: DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC
May 1st 2024Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
2 Commerce Drive
Cranbury, NJ 08512